Luteinizing Hormone-releasing Hormone Antagonists in Gynecology

  • J. B. Engel
  • K. Diedrich
Conference paper


The elucidation of the structure of LHRH in 1971 (Serially et al., 1971), a major breakthrough in endocrinology, was soon followed by the synthesis of LHRH superagonists (Karten and Rivier, 1986), which were more stable to cleavage and showed greater affinity to the LHRH receptor, mainly through amino acid substitutions at positions 6 and 10 of the native LHRH (Koch et al., 1977). These analogs were originally synthesized to mimic the action of LHRH but it was soon discovered that the compounds, after a flare-up of FSH and LH, led to pharmacological hypophysectomy via LHRH receptor depletion of the pituitary (Emons and Schally, 1994).


Luteinizing Hormone Ovarian Stimulation Uterine Fibroid GnRH Antagonist LHRH Agonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adamson G.D. and Pasta D.J. (1994). Surgical treatment of endometriosis-associated infertility: a meta-analysis compared with survival analysis. Am J Obstet Gynecol, 171, 1488–1505.PubMedGoogle Scholar
  2. Akman M.A., Erden H.F., Tosun S.B. et al. (2001). Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor respon-ders: results of a prospective randomized trial. Hum Reprod, 16, 868–870.PubMedCrossRefGoogle Scholar
  3. Al-Inany H. and Aboulghar M. (2002). GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod, 17, 874–885.PubMedCrossRefGoogle Scholar
  4. Albano C, Felberbaum R.E., Smitz J. et al. (2000). Ovarian stimulation with HMG: results of a prospective randomised phase III European study comparing the luteinizing-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod, 15, 526–531.PubMedCrossRefGoogle Scholar
  5. Ayala R.A., Meza E., Cervera A.R. et al. (1995). Effect of insulfated nafarelin (D-Nal-GnRH) upon uterine leiomyomata. Arch Med Res, 26, 523–526.Google Scholar
  6. Barbieri R.L. (1992). Hormonal therapy of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol, 166, 740–745.PubMedGoogle Scholar
  7. Bajusz S., Kovacs M., Gazdag M., Bokser L., Karashima T., Csernus V.J., Janaky T., Guoth J. and Schally A.V. (1988). Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects. Proc Natl Acad Sei, USA, 85, 1637–1641.CrossRefGoogle Scholar
  8. Buttram V.C. Jr and Reiter R.C. (1981). Uterine leiomyomata: etiology, symptomatology and management. Fertil Steril, 36, 433–435.PubMedGoogle Scholar
  9. Cramer S.F., Robertson A.L. Jr, Ziats N.P. et al. (1985). Growth potential of humane uterine leiomyomas: some in vitro observations and their implications. Obstet Gynecol, 66, 36–41.PubMedGoogle Scholar
  10. Daya S. (2003). A comparison of clinical pregnancy rates in the efficacy evaluation of GnRH agonist verus antagonist use for assisted reproduction — a meta-analysis using an intention-to-treat approach. 7th International Symposium on GnRH analogues in Cancer and Human Reproduction, Abstract 086,44.Google Scholar
  11. De Greef H., Mannaerts B. and Orleman E. (2001). Gonadotropin releasing hormone antagonist. Patent application WO 01/00227.Google Scholar
  12. Diedrich K., Diedrich C., Santos E. et al. (1994). Suppression of the endogenous LH surge by the GnRH antagonist cetrorelix during ovarian stimulation. Hum Reprod, 9, 788–791.PubMedGoogle Scholar
  13. Duijker I.-J., Klipping C., Willremsen W.-N. et al. (1998). Single- and multiple-dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist cetrorelix in healthy female volunteers. Hum Reprod, 23, 92–98.Google Scholar
  14. Edmonds D.K. (1996). Add-back therapy in the treatment of endometriosis: the European experience. Br J Obstet Gynecol, 103 (suppl 14), 10–14.Google Scholar
  15. Emons G., Westphalen S., Schulz K.-D. et al. (1999). First results of the GnRH antagonist cetrorelix in patients with ovarian cancer. Gynecol Endocrinol, 13, 064.Google Scholar
  16. Emons G., Schally A.V. (1994). The use of luteinizing hormone-releasing hormone agonists and antagonists in gynecological cancers. Hum Reprod, 9, 1364–1379.PubMedGoogle Scholar
  17. Engel J.B. (2002). Clomiphene-induced LH surges and cetrorelix. RBM Online, 5, 109–111.PubMedGoogle Scholar
  18. Engel J.B., Ludwig M., Felberbaum R. et al. (2002). Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to ’friendly IVF’? Hum Reprod, 17, 2022–2026.PubMedCrossRefGoogle Scholar
  19. Engel J.B., Ludwig M., Junge K. et al. (2003a). No influence of body weight on the pregnancy rate in patients treated with cetrorelix according to the single and multiple-dose protocol. Reprod BioMed Online, 6.Google Scholar
  20. Engel J.B., Olivennes F., Fanchin R. et al. (2003b). Single dose application of cetrorelix in combination with clomiphene for friendly IVF: results of a feasibility study. Reprod BioMed Online, 6, 444–447.CrossRefGoogle Scholar
  21. Erb K., Klipping C., Duijker I.-J. et al. (2001). Pharmakodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women. Fertil Steril, 75, 316–323.PubMedCrossRefGoogle Scholar
  22. Felberbaum R.E., Germer U., Ludwig M. et al. (1998). Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist cetrorelix. Hum Reprod, 13, 1660–1668.PubMedCrossRefGoogle Scholar
  23. Felberbaum R.E., Albano C., Ludwig M. et al. (2000). Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of GnRH-antago-nist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum Reprod, 15, 1015–1020.PubMedCrossRefGoogle Scholar
  24. Felberbaum R.E., Kuepker W., Krapp M. et al. (2001). Preoperative reduction of uterine fibroids in only 16 days by administration of a gonadotrophin-releasing hormone antagonist (Cetrotide). Reprod BioMed Online, 3, 14–18.PubMedCrossRefGoogle Scholar
  25. Filicori M., Hall D.A., Loughlin J.S. et al. (1983). A conservative approach to the management of uterine leimyoma: pituitary desensitization by a luteinizing hormone-releasing hormone analogue. Am J Obstet Gynecol, 7, 726–727.Google Scholar
  26. Franke H.R., van der Weijer P.H.M., Pennings T.M.M. et al. (2000). Gonadotropin-releas-ing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertil Steril, 74, 534–539.PubMedCrossRefGoogle Scholar
  27. Frydman R., Cornel C, de Ziegler D. et al. (1991). Prevention of premature luteinizing hormone and progesterone rise with a GnRH antagonist Nal-Glu in controlled ovarian hyperstimulation. Fertil Steril. 56, 923–927.PubMedGoogle Scholar
  28. Gonzalez-Barcena D., Banuelos Alvarez R., Pere Ochoa E. et al. (1997). Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist cetrorelix. Hum Reprod, 9, 2028–2035.CrossRefGoogle Scholar
  29. Hamm W.J. (2001). Broad experience with Cetrotide® (cetrorelix)-Results of a large multinational phase IIIB study. VIth International Symposium on GnRH Analogs in Cancer and Human Reproduction, Geneva, 2001.Google Scholar
  30. Healy D.L., Fraser H.M. and Lawson S.L. (1984). Shrinkage of a uterine fibroid after a subcutaneous infusion of LH-RH agonist. Br Med J, 289, 1267–1268.CrossRefGoogle Scholar
  31. Hughes E.G., Fedorkow D.M., Collins J.A. et al. (1993). A quantitative overview of controlled trials in endometriosis associated infertility. Fertil Steril, 59, 963–970.PubMedGoogle Scholar
  32. Karten M.J. and Rivier J.E. (1986). Gonoadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev, 7, 44–66.PubMedCrossRefGoogle Scholar
  33. Kettel L.M., Murphy A.A., Morales A.J. et al. (1993). Rapid regression of uterine leiomyomas in response to daily administration of gonadotrophin-releasing hormone antagonist. Fertil Steril, 60, 642–646.PubMedGoogle Scholar
  34. Koch Y., Baram T., Hazum E. et al. (1977). Resistance enzymatic degradation of LHRH analogs possessing increased biological activity. Biochem Biophys Res Commun, 74, 488–492.PubMedCrossRefGoogle Scholar
  35. Kovacs M., Schally A.V., Csernus B. et al. (2001). Luteinizing hormone-releasinig hormone (LHRH) antanonist cetrorelix down regulates the mRNA expression of pituitary receptors for LHRH by counteracting the stimulatory effect of endogenous LHRH. Proc Natl Acad Sci, 98, 1829–1834.PubMedCrossRefGoogle Scholar
  36. Küpker W., Felberbaum R.E., Krapp M. et al. (2002). Use of GnRH antagonists in the treatment of endometriosis. Reprod BioMed Online, 5, 12–16.PubMedCrossRefGoogle Scholar
  37. Leroy I., Dacrémont M.F., Brailly-Trabard S. et al. (1994). A single injection of a gonadotrophin-releasing hormone antagonist (cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge. Fertil Steril, 62, 461–467.PubMedGoogle Scholar
  38. Leather A.T., Studd J.W.W., Watso N.R. et al. (1993). The prevention of bone loss in young women treated with GnRH analogues with “add-back” estrogen therapy. Obstet Gynecol, 81, 104–107.PubMedGoogle Scholar
  39. Letterie G.S., Coddington C.C. and Winkel C.A. (1989). Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: a long-term follow-up. Fertil Steril, 51, 951–956.PubMedGoogle Scholar
  40. Ludwig M., Felberbaum R.E., Devroey P. et al. (2000). Significant reduction of the incidence of ovarian hyperstimulatin syndrome (OHSS) by using the LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Arch Gynecol Obstet, 264, 29–32.PubMedCrossRefGoogle Scholar
  41. Ludwig M., Katalinic A. and Diedrich K, (2001). Use of GnRH antagonists in ovarian stimulation for ART compared to the long protocol: a meta-analysis. Arch Gynecol Obstet, 265, 175–182.PubMedCrossRefGoogle Scholar
  42. Lumsden M.A., West C.P. and Baird D.T. (1987). Goserelin therapy before surgery for uterine fibroids. Lancet, I, 36–37.CrossRefGoogle Scholar
  43. Morgan J.E., O’Neill C.E., Coy D.H. et al. (1986). Antagonist analogs of luteinizing hormone-releasing hormone are mast cell secretagogues. Int Arch Allergy Appl Immun, 80, 70–75.CrossRefGoogle Scholar
  44. Nikolettos N., Al-Hasani S., Felberbaum R. etal. (2000). Gonadotrophin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders. Eur J Obstet Gynecol Recod Biol, 97, 202–207.CrossRefGoogle Scholar
  45. Oberyé J.J.J., Mannaerts B.M.J.L., Kleijn H.J. et al. (1999a). Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Orgalutran). Part I. Absolute bioavailability of 0.25 mg ganirelix after single subcutaneous injection in healthy female volunteers. Fertil Steril, 72, 1001–1005.CrossRefGoogle Scholar
  46. Obervé J.J.L., Mannaerts B.M.J.L., Huisman C.J. et al. (1999b). Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertil Steril, 72, 1006–1012.CrossRefGoogle Scholar
  47. Olivennes F., Fanchin R., Bouchard R et al. (1995). Scheduled administration of GnRH antagonist (cetrorelix) on day 8 of in vitro fertilization cycles: a pilot study. Hum Reprod, 10, 1382–1386.PubMedGoogle Scholar
  48. Olivennes R, Alvarez S., Bouchard R, Fanchin R., Salat-Baroux J. and Frydman R. (1998). The use of a GnRH-antagonist (cetrorelix) in a single-dose protocol in IVF-embryo transfer: a dose-finding study of 3 vs. 2 mg. Hum Reprod, 13, 2411–2414.PubMedCrossRefGoogle Scholar
  49. Olivennes F., Belaisch-Allart J., Emperaire J.C. et al. (2000). Prospective, randomised, controlled study of in vitro fertilization embryo transfer with a single dose of luteinizing hormone-releasing hormone (LHRH)-antagonist (cetrorelix) or a depot formula of a LHRH agonist (triptorelin). Fertil Steril, 73, 314–320.PubMedCrossRefGoogle Scholar
  50. Olivennes F., Cunha-Filho J.S., Fanchin R. et al. (2002). The use of GnRH antagonist in human reproduction. Hum Reprod Update, 8, 279–290.PubMedCrossRefGoogle Scholar
  51. Pinski J., Lamharzi M., Haimos G. et al. (1996). Chronic administration of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats. Endocrinology, 137, 3430–3436.PubMedCrossRefGoogle Scholar
  52. Schally A.V., Arimura A., Baba Y. et al. (1971). Isolation and properties of the FSH and LH-releasing hormone. Biophys Res Commun, 43, 393–399.CrossRefGoogle Scholar
  53. Schally A.V., Carter W.H., Parlow A.F. et al. (1970). Alteration of LH- and FSH-release in rats treated with clomiphene or its isomers. Am J Obstet Gynecol 107,1156-1167.PubMedGoogle Scholar
  54. Schally A.V. (1989). The use of LH-RH analogs in gynecology and tumor therapy. In Advances in Gynecology and Obstetrics: eds Belfort P., Pinotti J.A., Eskes T.K.A.B.. General Gynecology, Vol 6, pp 3–20, Carnforth, Parthenon.Google Scholar
  55. Schally A.V. (1999). LHRH analogues: their impact on the control of tumorigenesis. Peptides, 20, 1247–1262.PubMedCrossRefGoogle Scholar
  56. The European and Middle East Orgalutran Study Group (2001). Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges. Hum Reprod, 16, 644–651.CrossRefGoogle Scholar
  57. The European Orgalutran Study Group (2000). Treatment with the gonadotrophin releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized multicentre trial. Hum Reprod, 15, 1490–1498.CrossRefGoogle Scholar
  58. The North American Ganirelix Study Group (2001). Efficacy and safety of ganirelix acetate vs. leuprolide acetate in women undergoing controlled ovarian hyperstimula-tion. Fertil Steril, 75, 38–45.CrossRefGoogle Scholar
  59. Yano T., Minaguchi H., Taketani Y. et al. (2001). Cetrorelix in the treatment of uterine leiomyomas. VIth International Symposium on GnRH Analogues in Cancer and Human Reproduction. Geneva, 2001.Google Scholar

Copyright information

© Springer-Verlag Italia 2003

Authors and Affiliations

  • J. B. Engel
  • K. Diedrich

There are no affiliations available

Personalised recommendations